Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010.

Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010.
复制标题

胰腺癌患者的生存率提高了十年:SEER 数据库的时期分析,1981 年至 2010 年

DOI:
10.1038/srep06747
复制
发表时间:
2014-10-23
期刊:
影响因子:
4.6
通讯作者:
Wang J
Wang J
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Sun H;Ma H;Hong G;Sun H;Wang J

文献摘要

被引文献

相似文献

胰腺癌(PaCa)是一种侵袭性恶性肿瘤,死亡率高,预后差.为了评价过去30年胰腺癌患者的治疗结局,使用监测、流行病学和最终结果(SEER)登记研究的数据评估PaCa患者的生存率。1981年至2010年期间,从9个原始SEER登记研究中确定了63,530例胰腺癌患者。1年相对生存率(RSRs)每10年提高一次,从17.0%提高到19.9%再到28.2%(p< 0.0001),第3个10年的增幅大于第2个10年。然而,长期存活率仍然很低。在这30年中,5年RSRs从3.1%增加到4.4%再增加到6.9%-即,只有少数PaCa患者存活超过5年。此外,我们的分析表明,所有胰腺癌患者的生存率在较低的社会经济地位和黑人中较低。这些结果将有助于预测PaCa发病率和生存率的未来趋势,有助于通过消除可能影响结果的差异来更好地设计临床试验,从而改善PaCa的临床管理和结局。
Pancreatic cancer (PaCa) is an aggressive malignancy with a high mortality rate and a poor prognosis. To evaluate treatment outcomes of patients with pancreatic cancer over the past three decades, data from the Surveillance, Epidemiology and End Results (SEER) registries were used to assess the survival of patients with PaCa. A total of 63,530 patients diagnosed with pancreatic cancer between 1981 and 2010 were identified from nine original SEER registries. The 1-year relative survival rates (RSRs) improved each decade, from 17.0% to 19.9% to 28.2% (p< 0.0001), with a larger increase during the third decade than during the second decade. However, the long-term survival rates have remained very low. The 5-year RSRs increased from 3.1% to 4.4% to 6.9% over these three decades—i.e., still only few patients with PaCa survive more than 5 years. Furthermore, our analysis demonstrated that the survival rates for all the patients with pancreatic cancer were lower in patients of lower socioeconomic status and black race. These results will help predict future trends in PaCa incidence and survival, contribute to better-designed clinical trials by eliminating disparities that may affect the results and thereby improve the clinical management and outcomes of PaCa.